

REMARKS

Amendments to the specification.

Applicants believe no new matter is added by this amendment.

The Second Substitute Sequence Listing is being submitted in response to the Examiner's request to amend the specification to refer to corresponding SEQ ID NOs, which necessitates adding the sequences that appear in the specification to the Sequence Listing.

Support for the instant amendment to add sequences to the Sequence Listing can be found on page 25, line 11 of the specification. The Substitute Sequence Listing thus contains no new matter.


The annotated sheets showing changes made to Figs. 6A-6F were submitted with the previous amendment (the replacement sheets and annotated sheets exist in a single electronic file, thus both sets were printed and mailed, as evidenced by the transmittal letter sent with the response of 11 September 2007). The previously submitted replacement sheets and annotated sheets are being submitted with the response as well.

Support for the amendment to add the SEQ ID NOs. of the sequences found in Figs. 6A-6F as filed may be found in the Sequence Listing as filed and in Figs. 6A-6F as filed.

CONCLUSION

Applicants believe that no additional fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Mendel Biotechnology, Inc. Deposit Account No. **50-1025**.

Respectfully submitted,
MENDEL BIOTECHNOLOGY, INC.



Jeffrey M. Libby, Ph.D.
Reg. No. 48,251

Date: 21 January 2008

21375 Cabot Boulevard
Hayward, California 94545
Phone: (510) 259-6138
Fax: (510) 264-0254

JML/jml
File: MBI-0022CIP.RNCA.doc

Attachments:

- Transmittal Form
- Second Substitute Sequence Listing in Computer Readable Form
- Transmittal of Sequence Listing under 37 C.F.R. §§1.821-1.825 and §1.821(f)
- Figures 6A-6B, Replacement sheets and annotated sheets showing changes